Measuring the Vaccine Success Index: A Framework for Long-Term Economic Evaluation and Monitoring in the Case of Rotavirus Vaccination

• Published in: Vaccines (Basel) 2024-11, Vol.12 (11), p.1265
• Main Authors: Standaert, Baudouin, Raes, Marc, Ethgen, Olivier, Benninghoff, Bernd, Toumi, Mondher
• Format: Article
• Language: English
• Subjects: Age; Combined vaccines; Cost benefit analysis; Cost effectiveness; cost-impact; Disease; Dosage and administration; Economics; Hospitalization; Hospitals; Impact analysis; Infections; Methods; Monitoring; Pediatrics; Performance evaluation; Prevention; Risk factors; Rotavirus; Rotavirus infections; Source materials; Success; success index; Telemedicine; Time measurement; vaccination; Vaccine efficacy; Vaccines; Viral vaccines; Viruses
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12111265

New vaccination programs measure economic success through cost-effectiveness analysis (CEA) based on an outcome evaluated over a certain time frame. The reimbursement price of the newly approved vaccine is then often reliant on a simulated ideal effect projection because of limited long-term data availability. This optimal cost-effectiveness result is later rarely adjusted to the observed effect measurements, barring instances of market competition-induced price erosion through the tender process. However, comprehensive and systematic monitoring of the vaccine effect (VE) for the evaluation of the real long-term economic success of vaccination is critical. It informs expectations about vaccine performance with success timelines for the investment. Here, an example is provided by a 15-year assessment of the rotavirus vaccination program in Belgium (RotaBIS study spanning 2005 to 2019 across 11 hospitals). The vaccination program started in late 2006 and yielded sub-optimal outcomes. Long-term VE surveillance data provided insights into the infection dynamics, disease progression, and vaccine performance. The presented analysis introduces novel conceptual frameworks and methodologies about the long-term economic success of vaccination programs. The CEA evaluates the initial target vaccination population, considering vaccine effectiveness compared with a historical unvaccinated group. Cost-impact analysis (CIA) covers a longer period and considers the whole vaccinated and unvaccinated population in which the vaccine has direct and indirect effects. The economic success index ratio of CIA over CEA outcomes evaluates long-term vaccination performance. Good performance is close to the optimal result, with an index value ≤1, combined with a low CEA. This measurement is a valuable aid for new vaccine introductions. It supports the establishment of robust monitoring protocols over time.